New ALS Clinical Trial to Start for MediciNova’s Ibudilast

MediciNova, Inc., a biopharmaceutical company in La Jolla, California, has received FDA approval for a new Phase IIa clinical trial protocol for treating ALS patients with the small molecule, phosphodiesterase inhibitor MN-166, also called ibudilast (see April 2014 news, Sept 2015 news). This study will examine the drug’s effect on reducing brain microglial activation using a novel imaging biomarker for ALS called positron emission tomography (PET) [11] C-PBR28. The drug will be tested in 15 ALS patients over the course of 36 weeks and will be conducted in collaboration with Massachusetts General Hospital’s (MGH) Neurological Clinical Research Institute (NCRI) and Harvard Medical School.

Click here to read more.

disease-als topic-clinical topic-randd
Share this: